Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  CANADIAN NATIONAL STOCK EXCHANGE  >  Veritas Pharma       

VERITAS PHARMA

My previous session
Most popular
SummaryChartsNewsCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Veritas Pharma : Announces the Resignation of CEO, Dr. Lui Franciosi

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 06:14pm EST

VANCOUVER, British Columbia, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces the resignation of its President, CEO and Director, Dr. Lui Franciosi.  Company Interim CFO, Mr. Peter McFadden will fill the executive roles in the interim until a qualified replacement is found.

Dr. Franciosi stated, “It has been a challenging year with the regulatory delays in starting the Puerto Rico human study of CTL-X and the need to raise funds for medical cannabis research.  I am pleased to see the study approval has finally come through and that potential funding for Cannevert’s important scientific work has been secured, which means that the Veritas and Cannevert are now set for growth under new leadership. My work with Veritas has been a great experience, however I am extremely excited to give my primary focus to the science side of the business, and I will be available to the company at an advisory capacity to ensure seamless transition.”

Mr. McFadden stated, “The Veritas Board would like to thank Lui for his commitment to investors and to advancing the science behind medical cannabis.”  Dr. Franciosi will continue to assist both companies in an operational capacity.

About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 100% owned subsidiary Cannevert Therapeutics Ltd. (“CTL“), is advancing the science behind medical cannabis. It is the Company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas’ investment in CTL is led by a strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion-dollar markets according to Deloitte’s Insights and Opportunities.

Veritas Pharma Inc. is a publicly traded company in Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

For more information, please visit our website: www.veritaspharmainc.com

On behalf of the Board of Directors

"Mr. Peter McFadden"
Mr. Peter McFadden
Interim President and Chief Executive Officer

Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.

Contact Investor and Public Relations at:
Telephone: +1.604.827.5520
Email: ir@veritaspharmainc.com
Website: www.veritaspharmainc.com

The CSE has not reviewed, nor approved or disapproved the content of this press release.

Logo.PNG

Source: Veritas Pharma Inc.

2019 GlobeNewswire, Inc., source Press Releases

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERITAS PHARMA
02/12Veritas Pharma Enters into agreement to acquire Commercial Hemp and Cannabis ..
GL
02/11VERITAS PHARMA : Announces the Resignation of CEO, Dr. Lui Franciosi
AQ
02/11Veritas leads Puerto Rico partnership with approval of new Investigation Lice..
GL
02/06VERITAS PHARMA : to Proceed with Share Consolidation
AQ
02/04VERITAS PHARMA : to Proceed with Share Consolidation
AQ
02/04Veritas Pharma to Proceed with Share Consolidation
GL
01/16VERITAS PHARMA : Signs MOU with Santa Marta Gold Holdings for a Medical Cannabis..
AQ
01/15Veritas Pharma Signs MOU with Santa Marta Gold Holdings for a Medical Cannabi..
GL
2018VERITAS PHARMA : Makes Strategic Investment in Cannabis Production for Future Ca..
AQ
2018VERITAS PHARMA : Appoints Corporate Secretary & CFO; and Issues Stock Options
AQ
More news
Chart VERITAS PHARMA
Duration : Period :
Veritas Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Lui Franciosi President, CEO & Executive Director
Peter McFadden Chief Financial Officer
M. Scott Alexander Medical Director
Lorne Mark Roseborough Director
Blair Lowther Secretary & Director
Sector and Competitors
1st jan.Capitalization (M$)
VERITAS PHARMA1,110.00%0
CANOPY GROWTH CORP71.57%16 260
AURORA CANNABIS INC39.09%7 009
BEIJING TONGRENTANG CO., LTD.4.58%5 828
DONG-E-E-JIAO CO LTD--.--%4 179
CRONOS GROUP INC95.48%3 791